|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.92 SEK | +2.16% |
|
+22.54% | -16.28% |
| 06-23 | Citadel Back as Public Short Seller in Synact Pharma | FW |
| 06-18 | Edison Maintains Its Valuation for Synact Pharma After Trial Results | FW |
| Market Cap | 1.01B 104M 91.26M 83.86M 78.17M 148M 9.94B 151M 391M 4.89B 392M 383M 16.84B | P/E 2026 * |
-12.7x | P/E 2027 * | -24.9x |
|---|---|---|---|---|---|
| Enterprise Value | 989M 103M 89.67M 82.41M 76.81M 146M 9.77B 148M 385M 4.8B 385M 377M 16.54B | EV / Sales 2026 * |
7.13x | EV / Sales 2027 * | 48.8x |
| Free-Float |
70.28% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: SynAct Pharma AB
| 1 day | +2.16% | ||
| 1 week | +22.54% | ||
| Current month | -10.12% | ||
| 1 month | +36.90% | ||
| 3 months | +3.84% | ||
| 6 months | -15.72% | ||
| Current year | -16.28% |
| 1 week | 15.5 |  | 22.25 |
| 1 month | 7.05 | | 22.25 |
| Current year | 7.05 | | 24.4 |
| 1 year | 7.05 | | 25.3 |
| 3 years | 4.98 | | 124.6 |
| 5 years | 4.98 | | 146 |
| 10 years | 4.75 | | 146 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jeppe Øvlesen
CEO | Chief Executive Officer | 64 | 2013-12-31 |
Ann Kristin Led
DFI | Director of Finance/CFO | - | 2026-02-28 |
Kirsten Harting
CTO | Chief Tech/Sci/R&D Officer | - | 2024-02-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Sten Scheibye
BRD | Director/Board Member | 74 | 2024-03-19 |
Anders Kronborg
CHM | Chairman | 62 | 2024-03-19 |
Jeppe Øvlesen
BRD | Director/Board Member | 64 | 2024-03-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 03-09 | Buy | Chairman | 2,750 | 0.0052% | ||
| 03-08 | Quantass ApS
| Buy | Company | 7,900 | 0.0148% | |
| 03-08 | Buy | Executive/Senior Manager | 1,500 | 0.0028% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.16% | +22.54% | -10.75% | -74.71% | 102M | |
| +1.86% | +0.48% | +55.50% | +163.08% | 1,082B | |
| +3.57% | +3.29% | +68.60% | +61.03% | 633B | |
| +3.99% | +3.05% | +37.93% | +93.37% | 461B | |
| +3.86% | +1.64% | +32.57% | +24.89% | 339B | |
| -0.56% | +0.96% | +41.67% | +39.35% | 301B | |
| -0.08% | +1.30% | +32.15% | +44.48% | 292B | |
| -1.54% | +2.81% | -25.35% | -39.61% | 225B | |
| +3.55% | +4.41% | +25.45% | +66.28% | 202B | |
| +4.21% | +2.65% | +17.47% | +71.11% | 163B | |
| Average | +2.10% | +6.49% | +27.52% | +44.93% | 369.98B | |
| Weighted average by Cap. | +2.24% | +5.69% | +42.24% | +83.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 139M 14.39M 12.58M 11.56M 10.77M 20.43M 1.37B 20.74M 53.94M 673M 54M 52.84M 2.32B | 21.15M 2.19M 1.92M 1.76M 1.64M 3.11M 209M 3.16M 8.22M 103M 8.23M 8.05M 354M |
| Net income | 52.18M 5.41M 4.73M 4.35M 4.05M 7.68M 515M 7.8M 20.28M 253M 20.31M 19.87M 872M | -26.04M -2.7M -2.36M -2.17M -2.02M -3.84M -257M -3.89M -10.12M -126M -10.14M -9.92M -436M |
| Net Debt | -17.48M -1.81M -1.58M -1.46M -1.36M -2.57M -173M -2.61M -6.8M -84.82M -6.8M -6.66M -292M | 24.86M 2.58M 2.25M 2.07M 1.93M 3.66M 245M 3.72M 9.66M 121M 9.68M 9.47M 416M |
Employees
8
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-03 | SEK 18.92 | +2.16% | 202,458 |
| 26-07-02 | SEK 18.52 | -6.56% | 328,846 |
| 26-07-01 | SEK 19.82 | -5.84% | 580,556 |
| 26-06-30 | SEK 21.05 | +14.40% | 823,897 |
| 26-06-29 | SEK 18.40 | +19.17% | 605,579 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SYNACT Stock
Select your edition
All financial news and data tailored to specific country editions
